ACADIA PHARMACEUTICALS INC. (ACAD) Spending and interest coverage
- R&D / revenue · 12 months: Value 29.07%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 5.10%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 29.07% | Research and development expense / revenue. Period ending 2026-06-30. $331.01M ÷ $1.14B × 100 ≈ 29.07% |
| Stock-based compensation / revenue · 12 months | 5.10% | Share-based compensation / revenue. Period ending 2026-06-30. $58.05M ÷ $1.14B × 100 ≈ 5.10% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 331.01M USD | Research and Development Expense |
| Revenue | 1.14B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 58.05M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 86.37M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $331.01M | $1.14B | $58.05M | $86.37M | (m) | 29.07% | 5.10% | (m) | (m) |
| 2026-03-31 | $327.40M | $1.10B | $55.45M | $80.91M | (m) | 29.89% | 5.06% | (m) | (m) |
| 2025-12-31 | $328.80M | $1.07B | $52.13M | $104.81M | (m) | 30.69% | 4.87% | (m) | (m) |
| 2025-09-30 | $344.78M | $1.05B | $49.35M | $240.92M | (m) | 32.93% | 4.71% | (m) | (m) |
| 2025-06-30 | $323.55M | $1.02B | $62.33M | $236.81M | (m) | 31.76% | 6.12% | (m) | (m) |
| 2025-03-31 | $321.83M | $996.28M | $63.68M | $234.87M | (m) | 32.30% | 6.39% | (m) | (m) |
| 2024-12-31 | $303.25M | $957.80M | $67.05M | $230.79M | (m) | 31.66% | 7.00% | (m) | (m) |
| 2024-09-30 | $269.26M | $929.24M | $74.62M | $112.23M | (m) | 28.98% | 8.03% | (m) | (m) |
| 2024-06-30 | $359.62M | $890.53M | $67.00M | $22.82M | (m) | 40.38% | 7.52% | (m) | (m) |
| 2024-03-31 | $342.15M | $813.81M | $66.47M | $-4.58M | (m) | 42.04% | 8.17% | (m) | (m) |
| 2023-12-31 | $351.62M | $726.44M | $66.42M | $-73.38M | (m) | 48.40% | 9.14% | (m) | (m) |
| 2023-09-30 | $360.62M | $631.89M | $62.81M | $-154.39M | (m) | 57.07% | 9.94% | (m) | (m) |
| 2023-06-30 | $284.99M | $550.90M | $62.59M | $-127.48M | (m) | 51.73% | 11.36% | (m) | (m) |
| 2023-03-31 | $301.86M | $520.23M | $67.94M | $-164.16M | (m) | 58.03% | 13.06% | (m) | (m) |
| 2022-12-31 | $361.57M | $517.24M | $68.20M | $-223.60M | (m) | 69.91% | 13.19% | (m) | (m) |
| 2022-09-30 | $352.78M | $511.50M | $66.67M | $-222.19M | (m) | 68.97% | 13.03% | (m) | (m) |
| 2022-06-30 | $330.01M | $512.40M | $63.90M | $-206.63M | (m) | 64.40% | 12.47% | (m) | (m) |
| 2022-03-31 | $311.30M | $493.06M | $65.39M | $-216.68M | (m) | 63.14% | 13.26% | (m) | (m) |
| 2021-12-31 | $239.41M | $484.14M | $63.62M | $-170.44M | (m) | 49.45% | 13.14% | (m) | (m) |
| 2021-09-30 | $234.59M | $474.39M | $71.93M | $-192.94M | (m) | 49.45% | 15.16% | (m) | (m) |
| 2021-06-30 | $296.11M | $463.36M | $77.76M | $-263.54M | (m) | 63.90% | 16.78% | (m) | (m) |
| 2021-03-31 | $303.47M | $458.24M | $75.26M | $-263.84M | (m) | 66.22% | 16.42% | (m) | (m) |
| 2020-12-31 | $319.13M | $441.75M | $84.42M | $-286.59M | (m) | 72.24% | 19.11% | (m) | (m) |
| 2020-09-30 | $314.53M | $419.07M | $82.99M | $-275.82M | (m) | 75.05% | 19.80% | (m) | (m) |
| 2020-06-30 | $257.07M | $393.08M | $83.81M | $-235.34M | (m) | 65.40% | 21.32% | (m) | (m) |
| 2020-03-31 | $260.10M | $366.19M | $84.73M | $-248.43M | (m) | 71.03% | 23.14% | (m) | (m) |
| 2019-12-31 | $240.38M | $339.08M | $82.27M | $-246.54M | (m) | 70.89% | 24.26% | (m) | (m) |
| 2019-09-30 | $231.05M | $300.32M | $82.90M | $-257.42M | (m) | 76.93% | 27.60% | (m) | (m) |
| 2019-06-30 | $221.54M | $264.04M | $80.88M | $-273.27M | (m) | 83.90% | 30.63% | (m) | (m) |
| 2019-03-31 | $200.81M | $237.90M | $81.00M | $-280.26M | (m) | 84.41% | 34.05% | (m) | (m) |
| 2018-12-31 | $187.16M | $223.81M | $81.56M | $-247.44M | (m) | 83.63% | 36.44% | (m) | (m) |
| 2018-09-30 | $182.16M | $207.80M | $83.18M | $-250.18M | (m) | 87.66% | 40.03% | (m) | (m) |
| 2018-06-30 | $165.47M | $185.07M | $82.71M | $-254.55M | (m) | 89.41% | 44.69% | (m) | (m) |
| 2018-03-31 | $153.06M | $158.48M | $80.40M | $-258.51M | (m) | 96.58% | 50.73% | (m) | (m) |
| 2017-12-31 | $149.19M | $124.90M | $75.53M | $-292.41M | (m) | 119.45% | 60.47% | (m) | (m) |
| 2017-09-30 | $136.23M | $93.30M | $68.93M | $-301.78M | (m) | 146.01% | 73.88% | (m) | (m) |
| 2017-06-30 | $125.62M | $62.99M | $63.24M | $-307.87M | (m) | 199.43% | 100.40% | (m) | (m) |
| 2017-03-31 | $111.92M | $32.61M | $58.88M | $-311.36M | (m) | 343.17% | 180.54% | (m) | (m) |
| 2016-12-31 | $99.28M | $17.33M | $55.27M | $-272.81M | (m) | 572.87% | 318.88% | (m) | (m) |
| 2016-09-30 | $89.53M | $5.39M | $48.75M | $-240.15M | (m) | 1662.31% | 905.11% | (m) | (m) |
| 2016-06-30 | $82.45M | $157.00K | $44.01M | $-206.75M | (m) | 52514.65% | 28028.66% | (m) | (m) |
| 2016-03-31 | $80.35M | $61.00K | $37.62M | $-174.32M | (m) | 131719.67% | 61673.77% | (m) | (m) |
| 2015-12-31 | $73.87M | $61.00K | $40.19M | $-164.61M | (m) | 121096.72% | 65891.80% | (m) | (m) |
| 2015-09-30 | $71.58M | $92.00K | (m) | $-147.60M | (m) | 77809.78% | (m) | (m) | (m) |
| 2015-06-30 | $69.81M | $67.00K | (m) | $-133.60M | (m) | 104192.54% | (m) | (m) | (m) |
| 2015-03-31 | $65.23M | $94.00K | (m) | $-115.82M | (m) | 69392.55% | (m) | (m) | (m) |
| 2014-12-31 | $60.60M | $120.00K | (m) | $-93.23M | (m) | 50501.67% | (m) | (m) | (m) |
| 2014-09-30 | $50.34M | $109.00K | (m) | $-76.84M | (m) | 46188.07% | (m) | (m) | (m) |
| 2014-06-30 | $40.65M | $335.00K | (m) | $-62.66M | (m) | 12133.43% | (m) | (m) | (m) |
| 2014-03-31 | $33.96M | $758.00K | $8.29M | $-50.09M | (m) | 4480.21% | 1093.80% | (m) | (m) |
| 2013-12-31 | $26.72M | $1.15M | $5.71M | $-38.30M | (m) | 2333.80% | 498.78% | (m) | (m) |
| 2013-09-30 | $23.70M | $1.49M | $4.09M | $-32.95M | (m) | 1592.61% | 274.73% | (m) | (m) |
| 2013-06-30 | $20.84M | $4.73M | $2.69M | $-24.55M | (m) | 441.03% | 56.81% | (m) | (m) |
| 2013-03-31 | $18.20M | $4.87M | $2.10M | $-20.82M | (m) | 373.47% | 43.07% | (m) | (m) |
| 2012-12-31 | $18.79M | $4.91M | $1.93M | $-20.89M | (m) | 383.00% | 39.33% | (m) | (m) |
| 2012-09-30 | $18.32M | $5.12M | $1.79M | $-19.38M | (m) | 358.10% | 34.94% | (m) | (m) |
| 2012-06-30 | $18.07M | $2.22M | $1.70M | $-22.07M | (m) | 813.82% | 76.54% | (m) | (m) |
| 2012-03-31 | $17.92M | $2.08M | $1.64M | $-23.22M | (m) | 860.61% | 78.58% | (m) | (m) |
| 2011-12-31 | $17.31M | $2.07M | $1.60M | $-22.85M | (m) | 837.40% | 77.31% | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $20.58M | $42.13M | $1.58M | $15.09M | (m) | 48.84% | 3.76% | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $41.59M | $6.40M | $2.13M | $-45.47M | (m) | 649.87% | 33.35% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |